Loading
A phase 2 trial of Vismodegib in basal cell carcinoma, run by Stamford Pharmaceuticals, Inc., now recruiting.
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma is a phase 2 interventional study registered as NCT06344052 by Stamford Pharmaceuticals, Inc., with 80 participants planned, started 2024-04-09 and due to reach its primary completion in 2026-09-30. Interventions recorded: SP-002, Vismodegib. Conditions listed: Basal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Shares Hedgehog pathway inhibitors, Vismodegib, Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Shares Hedgehog pathway inhibitors, Vismodegib, Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Shares Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares Hedgehog pathway inhibitors, Vismodegib, Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/